This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Qulipta® Alternatives

Qulipta®

(Atogepant)
Qulipta
    Migraine
  • Emgality®
  • Vyepti®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
Prescription Only
Qulipta is a prescription medication that is used as a preventative treatment for episodic migraines. It is a tablet that is taken once daily. The most common side effects are fatigue, nausea, and constipation. Qulipta is FDA approved for the following indications: Migraine prevention.

Ajovy®

(Fremanezumab)
Ajovy
    Migraine
  • Emgality®
  • Vyepti®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
Prescription Only
Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions. Ajovy is FDA approved for the following indications: Migraine prevention.

Dosage & Administration

Administration
Oral
Subcutaneous
Dosing
10 mg, 30 mg, or 60 mg once daily. Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each)
Latin Shorthand
10mg qd, 30mg qd or 60mg qd Renal Impairment: 10mg qd
225 mg/mo or 675 mg q3mo

Financial Assistance

Copay
$0
$5
Annual Cap
$6,000
Patient specific maximum benefit.
Assistance Expiration
12 30-day prescription fills
12/31/2023
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Qulipta® vs. Emgality®
  • Qulipta® vs. Vyepti®
  • Qulipta® vs. Aimovig®
  • Qulipta® vs. Nurtec odt®
  • Qulipta® vs. Ubrelvy®

Relevant Resources

Ajovy
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Qulipta
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.